Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating today. Ami Fadia has given his Hold rating ...

After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...

Talkiatry to offer new resources and expand access to care for women experiencing postpartum mental health challenges by virtually connecting them with a provider from the comfort of their own home ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage said it will continue to test dalzanemdor as a treatment for Huntington's disease and expects to report its mid-stage ...

Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...